Recombinant human Angiotensin-converting enzyme 2 (ACE2) expressed in HEK293 cells. Extracellular domain of human ACE2 (aa 1-740) is fused to the N-terminus of the Fc region
of human IgG1.
Binds to the Spike protein of the coronavirus SARS-CoV-2.
<0.001 EU/μg (LAL test).
1 mg/ml after reconstitution. Lyophilized. Contains PBS.
Reconstitute with 100 μl endotoxin-free water.
Cell culture and/or animal studies, In vitro, COVID-19
Shipped on ice packs. Upon receipt, store the product at the temperature recommended below.
Stable for at least 6 months after receipt when stored at -20°C.
After opening, prepare aliquots and store at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. Avoid freeze/thaw cycles. For maximum product recovery after
thawing, centrifuge the vial before opening the cap.
This BioVendor product is furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Blood pressure regulation and NO metabolism, Cardiovascular disease, Immune Response, Infection and Inflammation, Pulmonary diseases, Renal disease, COVID-19
Angiotensin-converting enzyme 2 (ACE2) is an ectoenzyme (carboxypeptidase) with an extracellular catalytic domain that predominantly localizes at the plasma membrane and is thereby able to hydrolyze circulating peptides. ACE2 has approximately 42% sequence identity with ACE, and its cytoplasmic and transmembrane domains show 48% homology to the protein collectrin that plays a critical role in the amino acid absorption of the kidney. ACE2 converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. ACE2 is involved in the regulation of systemic blood pressure and has direct effects on cardiac functions. It is expressed predominantly in endothelial cells of the lung, gut, heart and kidney. ACE2 together with the protease TMPRSS2 acts as a functional receptor for SARS coronavirus as well as for the new highly pathogenic coronavirus, 2019-nCoV/SARS-CoV-2, which is cause for pneumonia COVID-19. It has been shown that human recombinant soluble ACE2 can significantly block early stages of SARS-CoV-2 infections.